Molecular characterisation of pancreatic ductal adenocarcinoma in patients under 40

Journal of Clinical Pathology

Volumn 59, Issue 6, 2006, Pages 580-584

  Bergmann, F ^a   Aulmann, S ^a   Wente, M N ^a   Penzel, R ^a   Esposito, I ^a   Kleeff, J ^a   Friess, H ^a   Schirmacher, P ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; PROTEIN P53; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ADENOSQUAMOUS CARCINOMA; ADULT; ARTICLE; CANCER SUSCEPTIBILITY; CHRONIC PANCREATITIS; CIGARETTE SMOKING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC DISORDER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MISMATCH REPAIR; MOLECULAR GENETICS; MUTATIONAL ANALYSIS; PANCREAS ADENOCARCINOMA; PANCREAS DUCT; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGE FACTORS; CARCINOMA, PANCREATIC DUCTAL; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GENES, RAS; HUMANS; MUTATION, MISSENSE; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS;

EID: 33745068434     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2005.027292     Document Type: Article

References (37)

1. Lüttges J, Stigge C, Pacena M, et al. Rare ductal adenocarcinoma of the pancreas in patients younger than age 40 years. An analysis of its features and a literature review. Cancer 2004;100:173-82.
2. Solcia E, Capella C, Klöppel G. Tumors of the pancreas. In: Rosai J, Sobin LH, eds. Atlas of tumor pathology, 3rd Series, Fascicle 20. Washington, DC: Armed Forces Institute of Pathology, 1997.
3. Ghadirian P, Lynch HT, Krewski D. Epidemiology of pancreatic cancer: an overview. Cancer Detect Prev 2003;27:87-93.
4. Von der Heijden MS, Yeo Q, Hruban RH, et al. Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res 2003;63:2585-8.
5. Klöppel G, Hruban RH, Longnecker DS, et al. Ductal adenocarcinoma of the pancreas. In: Hamilton SR, Aaltonen LA, eds. World Health Organization classification of tumours. Pathology and genetics of tumours of the digestive system. Lyon: IARC Press, 2000.
6. Tersmette AC, Petersen GM, Offerhaus GJ, et al. Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res 2001;7:738-44.
7. Smith JH III, Baugh C, Reppun T. Obstructive jaundice secondary to pancreatic adenocarcinoma in a seven-year-old male. J Pediatr Surg 1985;20:184-5.
8. Reimer RR, Fraumeni JF Jr, Ozols RF, et al. Pancreatic cancer in father and son. Lancet 1977;1:911.
9. Ehrenthal D, Haeger L, Griffin T, et al. Familial pancreatic adenocarcinoma in three generations. A case report and a review of the literature. Cancer 1987;59:1661-4.
10. Bowlby LS. Pancreatic adenocarcinoma in an adolescent male with Peutz-Jeghers syndrome. Hum Pathol 1986;17:97-9.
11. Thatcher BS, May ES, Taxier MS, et al. Pancreatic adenocarcinoma in a patient with Peutz-Jeghers syndrome-a case report and literature review. Am J Gastroenterol 1986;81:594-7.
12. Karak PK, Mukhopadhyay S, Singh SP, et al. Multiple primary coexisting malignancy in young patients. Trop Gastroenterol 1994;15:99-103.
13. Walpole IR, Cullity G. Juvenile polyposis: a case with early presentation and death attributable to adenocarcinoma of the pancreas. Am J Med Genet 1989;32:1-8.
14. Tavassoli FA, Lynch RG. Occult adenocarcinoma of the pancreas in a 17-year-old patient with immunosuppressed leukaemia. Gastroenterology 1974;66:1054-7.
15. Lack EE, Cassady JR, Levey R, et al. Tumors of the exocrine pancreas in children and adolescents. A clinical and pathologic study of eight cases. Am J Surg Pathol 1983;7:319-27.
16. Deutsch M, Rosenstein MM, Ramanathan RK. Pancreatic cancer in a young adult after treatment for Hodgkin's disease. Clin Oncol 1999;11:280-2.
17. Simchuk E, Welch JP, Orlando R. Antepartum diagnosis of pancreatic carcinoma: a case report. Conn Med 1995;59:259-62.
18. Neuget AL, Habibul A, Robinson E. Pancreas cancer as a second primary malignancy: a population based study. Cancer 1995;16:589-92.
19. Hruban RH, Wilentz RE, Kern SE. Genetic progression in pancreatic ducts. Am J Pathol 2000;156:1821-5.
20. Schneider G, Schmid RM. Genetic alterations in pancreatic carcinoma. Mol Cancer 2003;2:15.
21. Hingorani SR, Petricoin EF, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003;4:437-50.
22. Rozenblum E, Schutte M, Goggins M, et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997;57:1731-4.
23. Schutte M, Hruban RH, Geradts J, et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997;57:3126-30.
24. Wilentz RE, Iacobuzio-Donahue CA, Argani P, et al. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 2000;60:2002-6.
25. Lüttges J, Galehdari H, Broker V, et al. Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis. Am J Pathol 2001;158:1677-83.
26. Biankin AV, Morey AL, Lee CS, et al. DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. J Clin Oncol 2002;20:4531-42.
27. Tascilar M, Skinner HG, Rosty C, et al. The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res 2001;7:4115-21.
28. Lüttges J, Neumann S, Jesnowski R, et al. Lack of apoptosis in PanIN-1 and PanIN-2 lesions associated with pancreatic ductal adenocarcinoma is not dependent on K-ras status. Pancreas 2003;27:e57-62.
29. Calhoun ES, Jones JB, Ashfaq R, et al. BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol 2003;163:1255-60.
30. Peyssonnaux C, Eychene A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 2001;93:53-62.
31. Caduff RF, Svoboda-Newman SM, Ferguson AW, et al. Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors. Am J Surg Pathol 1999;23:323-8.
32. Vant Veer LJ, Burgering BM, Versteeg R, et al. N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol Cell Biol 1989;9:3114-6.
33. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-32.
34. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
35. Ishimuro N, Yamasawa K, Karim Rumi MA, et al. BRAF and K-ras gene mutations in human pancreatic cancers. Cancer Lett 2003;199:169-73.
36. Collisson EA, De A, Suzuki H, et al. Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade. Cancer Res 2003;63:5669-73.
37. Gamett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004;6:313-9.